BIOIO-1001

Asset

Modulates mTOR/insulin and NAD+ pathways through SIRT3-centered lipid metabolism, reducing inflammation and fibrosis in preclinical models.

Stage: Preclinical
Modality: Small molecule
Target: Not known; 2
Indications: 0
Trials: 1
Developer

Indications

2

Amyotrophic lateral sclerosis
Preclinical, doi.org, Jan 19, 2023
Metabolic dysfunction-associated steatohepatitis
Preclinical, doi.org, Jan 19, 2023

In the full profile

Owner and partners1
Evidence for its targets1
Competitors12
Aging relevance2

Every asset’s record: target, stage, trials and the evidence behind it.